Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Rev. bras. cir. plást ; 38(1): 1-5, jan.mar.2023. ilus
Article in English, Portuguese | LILACS-Express | LILACS | ID: biblio-1428711

ABSTRACT

Introduction: Lipodystrophy is an important complication of HIV and has different clinical manifestations, such as lipoatrophy of the face, buttocks, and limbs and accumulation of fat in the abdominal and cervical regions. Lipodystrophy has aesthetic and psychosocial consequences, stigmatizing and affecting patients' quality of life. The objective is to evaluate the epidemiology and treatments performed in patients treated at the HIV-related Lipodystrophy Outpatient Clinic at Hospital das Clínicas da Faculdade de Medicina de Botucatu. Method: The study was conducted retrospectively, with port analysis of patients treated between June 2012 and December 2019, at Hospital das Clínicas da Faculdade de Medicina de Botucatu, in Botucatu, SP, Brazil. Results: The medical records of 153 individuals were analyzed, 79 male and 74 female patients. The mean age was 45.6 years. The referrals came from 48 cities in four states. Caucasian patients accounted for 74.5% of the consultations. The complaint of facial lipodystrophy was reported by 52.9% of the patients. The most common invasive procedure was facial filling with polymethylmethacrylate (PMMA) in 62 patients. Gluteal implants were the most common surgery on six occasions. Conclusion: The data found show a higher proportion of female patients with complaints of lipodystrophy when compared to general data of patients with HIV. The white race was predominant, and the main complaint of lipodystrophy was facial atrophy. Facial filling with PMMA was the most common procedure.


Introdução: A lipodistrofia é uma importante complicação do HIV e apresenta diferentes manifestações clínicas, como lipoatrofia de face, glúteos e membros, e acúmulo de gordura em região abdominal e cervical. A lipodistrofia apresenta consequências estéticas e psicossociais, que são estigmatizantes e afetam a qualidade de vida dos pacientes. O objetivo é avaliar a epidemiologia e os tratamentos realizados nos pacientes atendidos no Ambulatório de Lipodistrofia relacionada ao HIV do Hospital das Clínicas da Faculdade de Medicina de Botucatu. Método: O estudo foi realizado de maneira retrospectiva, com análise de portuário dos pacientes atendidos entre junho de 2012 e dezembro de 2019, no Hospital das Clínicas da Faculdade de Medicina de Botucatu, em Botucatu, SP, Brasil. Resultados: Os prontuários de 153 indivíduos foram analisados, sendo 79 pacientes do sexo masculino e 74 do sexo feminino. A média de idade foi 45,6 anos. Os encaminhamentos tiveram origem de 48 cidades, de quatro estados. Pacientes da raça branca totalizaram 74,5% dos atendimentos. A queixa de lipodistrofia de face foi referida por 52,9% dos pacientes. O procedimento invasivo mais realizado foi o preenchimento facial com polimetilmetacrilato (PMMA), em 62 pacientes. A inclusão de implantes glúteos foi a cirurgia mais realizada, em seis ocasiões. Conclusão: Os dados encontrados mostram maior proporção de pacientes do sexo feminino com queixa de lipodistrofia, quando comparados a dados gerais de pacientes com HIV. A raça branca foi predominante e a principal queixa de lipodistrofia foi a atrofia facial. O preenchimento facial com PMMA foi o procedimento mais realizado

2.
Cureus ; 14(9): e28960, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36237744

ABSTRACT

Human immunodeficiency virus (HIV) primarily affects the immune systems, which, if progressed, will lead to acquired immunodeficiency syndrome (AIDS). Currently, there is no effective cure for the disease, and patients are affected lifelong, but there are antiretroviral medications that can control the disease's symptoms and progression. In addition, taking precautions during sexual contact, especially in the male homosexual population, while handling the patient's bodily fluids such as blood and saliva, and during childbirth by an infected mother is necessary to prevent the transmission of the virus. We used 15 studies, including systematic reviews and meta-analyses, observation studies, randomized clinical trials, and comprehensive reviews, to determine how HIV interferes with heart disease, increasing morbidity and mortality. We have used specific inclusion and exclusion criteria, focusing on specified age groups within a particular timeline. Some of the included studies found that many side effects from antiretroviral drugs can impact heart conditions, along with HIV, while others did not show a strong correlation between HIV and some heart diseases. In conclusion, after reviewing the literature, the results are inconclusive. More extensive trials focusing on the impact HIV has on heart disease are required to establish a strong correlation between HIV and heart disease to prevent morbidity and mortality.

3.
AIDS Care ; 34(8): 1031-1040, 2022 08.
Article in English | MEDLINE | ID: mdl-34082636

ABSTRACT

The aim of this study was to determine the effect of lipodystrophy on self-esteem and adherence to antiretroviral therapy (ART) in people living with HIV (PLHIV). A cross-sectional and comparative study was carried out in an infection clinic, with 125 patients with lipodystrophy and 125 without lipodystrophy. Sociodemographic, clinical and epidemiological data were collected, using the Rosenberg Self-Esteem Scale and Assessment of Adherence to Antiretroviral Treatment Questionnaire (CEAT-VIH). Descriptive statistics and univariate and multivariate logistic regression analysis were used. Of the total sample, 57.2% had unsatisfactory self-esteem and 57.6% adequate adherence to ART. Self-esteem was lower in PLHIV with lipodystrophy (66.4%). PLHIV with monthly income less than or equal to two minimum wages (P < 0.001) and those with lipodystrophy had more unsatisfactory self-esteem (P < 0.001). Catholics had better self-esteem (P = 0.012), when compared to those without religion. Patients with monthly income less than or equal to two minimum wages (P = 0.021) and people with unsatisfactory self-esteem had more inadequate adherence to ART (P = 0.001). Catholics had better adherence to antiretrovirals (P = 0.007). In conclusion, lipodystrophy and low income negatively affect the self-esteem of PLHIV. Low income and unsatisfactory self-esteem make adherence to ART difficult. Religion is a protective factor for satisfactory self-esteem and adherence to antiretrovirals.


Subject(s)
HIV Infections , Lipodystrophy , Anti-Retroviral Agents/therapeutic use , Cross-Sectional Studies , HIV Infections/drug therapy , Humans , Medication Adherence , Self Concept
4.
Fisioter. Mov. (Online) ; 35: e35117, 2022. tab
Article in English | LILACS | ID: biblio-1384949

ABSTRACT

Abstract Introduction: Highly active antiretroviral therapy (HAART) transformed HIV from a fatal disease to a chronic one, but it has adverse effects, such as the lipodystrophy syndrome, characterized by morphological and metabolic changes, such as reduced bone mineral density (BMD), potentiating morbidities and mortality. Strength training (ST) aims to increase BMD, due to the osteogenic effect. Objective: To verify the impact of strength training on BMD in people with HIV. Methods: This is a quasi-experimental study, which included 40 people with a mean age of 50 ± 6 years, separated into trained group (TG, n = 20) and control group (CG, n = 20), with reduction in BMD, HIV-positive, using HAART and without exercising. BMD was assessed by DEXA in the lumbar spine, femoral neck and distal 1/3 of the radius, before and after 12 weeks, with the GT submitted to 36 ST and the CG without physical training in the DEXA evaluation in the same time interval. Results: TG had a significant increase with great effect on BMD in all segments: lumbar spine (p = 0.001; ES: 1.87), femoral neck (p = 0.003; ES: 2.20) and 1/3 distal of the radius (p = 0.001; ES: 1.81). Meanwhile, CG group showed a significant reduction with great effect on the femoral neck (p = 0.020; ES: 2.56) and 1/3 distal of the radius (p = 0.015; ES: 2.93), while the lumbar spine showed a great effect to reduce BMD (p = 0.293; ES: 1.78). Conclusion: ST can be used as a therapeutic resource to increase BMD in people with HIV, contributing to the advancement in the search for non-drug therapeutic practices.


Resumo Introdução: A terapia antirretroviral altamente ativa (HAART) transformou o HIV em uma doença crônica, apresentando efeitos adversos como a síndrome da lipodistrofia, caracterizada por alterações morfológicas e metabólicas, como redução da densidade mineral óssea (DMO), potencializando morbidades e mortalidades. O treinamento de força (TF) tem como proposta aumentar a DMO, devido ao efeito osteogênico. Objetivo: Verificar o impacto do TF na DMO em pessoas com HIV. Métodos: Trata-se de um estudo quase-experimental que incluiu 40 pessoas com idade média de 50 ± 6 anos, separadas em grupo treinado (GT, n = 20) e grupo controle (GC, n = 20), com redução na DMO, HIV positivo, usando HAART e sem praticar exercícios físicos. A DMO foi avaliada pelo DEXA na coluna lombar, colo do fêmur e 1/3 distal do rádio, antes e após 12 semanas, com o GT submetido a 36 sessões de TF e o GC sem exercício durante o mesmo período. Resultados: O GT teve aumento significante com grande efeito em todos os segmentos: coluna lombar (p = 0,001; ES: 1,87), colo do fêmur (p = 0,003; ES: 2,20) e 1/3 distal do rádio (p = 0,001; ES: 1,81), enquanto o GC apresentou redução significante com grande efeito no colo do fêmur (p = 0,020; ES: 2,56), 1/3 distal do rádio (p = 0,015; ES: 2,93) e apenas grande efeito na coluna lombar (p = 0,293; ES: 1,78). Conclusão: O TF pode ser utilizado como recurso terapêutico para aumentar a DMO em pessoas com HIV, contribuindo para o avanço nas buscas de práticas terapêuticas não medicamentosas.


Subject(s)
Humans , Middle Aged , Bone Density , HIV-Associated Lipodystrophy Syndrome , Resistance Training , Exercise
5.
Rev. bras. cir. plást ; 36(3): 309-314, jul.-set. 2021. tab, graf
Article in Portuguese | LILACS-Express | LILACS | ID: biblio-1365567

ABSTRACT

RESUMO Introdução: O Brasil apresenta um dos melhores programas de combate ao HIV do mundo e uma das características dessa abordagem é a multidisciplinaridade, onde a cirurgia plástica está envolvida. Objetivo: Realizar uma revisão não sistemática do que já foi publicado sobre HIV por cirurgiões plásticos brasileiros, analisando os principais temas estudados. Métodos: Pesquisas no PubMED, EMBASE, MEDLINE, LILACS, SciELO, Revista Brasileira de Cirurgia Plástica com os seguintes termos: "plastic surgery HIV", "plastic surgery AIDS", "HIV cirurgia plástica", "AIDS cirurgia plástica", "HIV" e "AIDS. Resultados: No total encontramos 862 artigos e após selecionar os escritos por cirurgiões plástico brasileiros, chegamos a um número final de 15, produzidos por 10 instituições de 5 estados brasileiros. O tema mais abordado foi lipodistrofia em 13 publicações. Discussão: Dos artigos selecionados, fica clara a concentração na região Sudeste. O tema mais abordado foi a lipodistrofia e os artigos sobre este foram publicados posteriores à Portaria GM/MS 2582. Áreas como neoplasia cutânea, genética e cirurgia para mudança de sexo não foram alvos de publicações, embora em outros países já haja conteúdo relacionado a HIV e cirurgia plástica produzido. Conclusão: Apesar de publicações de qualidade ainda há áreas em que a pesquisa da cirurgia plástica brasileira necessita explorar em relação ao HIV/AIDS.


ABSTRACT Introduction: Brazil presents one of the best HIV programs globally, and one of the characteristics of this approach is multidisciplinarity, where plastic surgery is involved. Objective: To conduct a non-systematic review of what has already been published on HIV by Brazilian plastic surgeons, analyzing the main themes studied. Methods: Research at PubMed, EMBASE, MEDLINE, LILACS, SciELO, Revista Brasileira de Cirurgia Plástica with the following terms: "plastic surgery HIV", "plastic surgery AIDS", "HIV plastic surgery", "AIDS plastic surgery", "HIV" and "AIDS. Results: We found 862 articles, and after selecting those written by Brazilian plastic surgeons, we reached a final number of 15, produced by 10 institutions from 5 Brazilian states. The most addressed theme was lipodystrophy in 13 publications. Discussion: From the selected articles, it is clear the concentration in the Southeast region. The most addressed theme was lipodystrophy, and the articles on it were published after ordinance GM/MS 2582. Areas such as skin cancer, genetics and surgery for gender reassignment have not been published, although there is already content related to HIV and plastic surgery in other countries. Conclusion: Despite quality publications, there are still areas in which Brazilian plastic surgery research needs to explore concerning HIV/AIDS.

6.
Endocrinol Metab (Seoul) ; 34(2): 95-105, 2019 06.
Article in English | MEDLINE | ID: mdl-31257738

ABSTRACT

In the current era of effective antiretroviral therapies (ARTs), human immunodeficiency virus (HIV) infection became a chronic disorder that requires long term follow-up. Among other medical issues, these patients may develop endocrine problems, specific to HIV infection and its treatment. The purpose of this review is to give an overview of common endocrine complications associated with HIV infection, and to propose diagnostic and therapeutic strategies. HIV can affect the endocrine system at several levels. Adrenal and gonadal dysfunction, osteoporosis with increased fracture risk, dyslipidemia with increased cardiovascular risk, are some of the endocrine disorders prevalent in HIV-infected patients that may negatively influence quality of life, and increase morbidity and mortality. While ARTs have dramatically increased life expectancy in the HIV-infected population, they are not devoid of adverse effects, including endocrine dysfunction. Physicians caring for HIV-infected patients should be knowledgeable and exercise a high index of suspicion for the diagnosis of endocrine abnormalities, and in particular be aware of those that can be life threatening. Endocrine evaluation should follow the same strategies as in the general population, including prevention, early detection, and treatment.


Subject(s)
Anti-HIV Agents/therapeutic use , Endocrine System Diseases/virology , HIV Infections/complications , HIV Infections/drug therapy , Bone Diseases/virology , Endocrine System Diseases/diagnosis , Endocrine System Diseases/therapy , Gonadal Disorders/veterinary , Humans , Metabolic Diseases/virology , Pituitary Diseases/virology , Thyroid Diseases/virology
7.
Article in English | WPRIM (Western Pacific) | ID: wpr-763706

ABSTRACT

In the current era of effective antiretroviral therapies (ARTs), human immunodeficiency virus (HIV) infection became a chronic disorder that requires long term follow-up. Among other medical issues, these patients may develop endocrine problems, specific to HIV infection and its treatment. The purpose of this review is to give an overview of common endocrine complications associated with HIV infection, and to propose diagnostic and therapeutic strategies. HIV can affect the endocrine system at several levels. Adrenal and gonadal dysfunction, osteoporosis with increased fracture risk, dyslipidemia with increased cardiovascular risk, are some of the endocrine disorders prevalent in HIV-infected patients that may negatively influence quality of life, and increase morbidity and mortality. While ARTs have dramatically increased life expectancy in the HIV-infected population, they are not devoid of adverse effects, including endocrine dysfunction. Physicians caring for HIV-infected patients should be knowledgeable and exercise a high index of suspicion for the diagnosis of endocrine abnormalities, and in particular be aware of those that can be life threatening. Endocrine evaluation should follow the same strategies as in the general population, including prevention, early detection, and treatment.


Subject(s)
Humans , Anti-Retroviral Agents , Diabetes Mellitus , Diagnosis , Dyslipidemias , Endocrine System Diseases , Endocrine System , Follow-Up Studies , Gonads , HIV Infections , HIV , HIV-Associated Lipodystrophy Syndrome , Hyperlipidemias , Life Expectancy , Mortality , Osteoporosis , Quality of Life
8.
Rev. bras. cir. plást ; 32(3): 398-401, jul.-set. 2017.
Article in English, Portuguese | LILACS | ID: biblio-868283

ABSTRACT

INTRODUÇÃO: Desde a introdução do tratamento do HIV com uso da terapia antirretroviral altamente ativa, a mortalidade por essa doença foi reduzida drasticamente em todo o mundo. Um dos parefeitos relacionados à utilização desses fármacos é a lipodistrofia glútea. O objetivo deste trabalho é verificar o impacto da correção dessa deformidade na qualidade de vida de pacientes com HIV. MÉTODOS: Foi conduzido um estudo de coorte histórica com 23 pacientes submetidos à gluteoplastia com implante intramuscular, entre janeiro de 2010 e dezembro de 2014, avaliando a qualidade de vida por meio do em Nottingham Health Profile em. As informações foram coletadas de julho a agosto de 2015. A análise estatística foi feita utilizando-se o em Related-Samples McNemar Test em. RESULTADOS: strong Houve diferença significativa entre o pré-operatório e pós-operatório em 19 das 38 perguntas. CONCLUSÃO: É possível afirmar que a reconstrução glútea melhora a qualidade de vida de pacientes HIV positivos acometidos por lipodistrofia glútea relacionada a antirretrovirais.


INTRODUCTION: Since the introduction of highly active antiretroviral therapy for the treatment of human immunodeficiency virus (HIV), disease mortality has been dramatically reduced worldwide. One related side effect from the use of these drugs is gluteal lipodystrophy. The aim of this study is to assess the quality-of-life impact of correcting this deformity in HIV patients. METHODS: A historical cohort study was conducted between January 2010 and December 2014 with 23 patients, assessing the quality of their lives using the Nottingham Health Profile. A statistical analysis was performed using the McNemar test for related samples. RESULTS: There was a significant difference between preoperative and postoperative response in 19 of the 38 questions. CONCLUSION: We may say that gluteal reconstruction plays a role in improving quality of life for HIV patients who have been affected by antiretroviral related gluteal lipodystrophy.


Subject(s)
Humans , Male , Female , Middle Aged , History, 21st Century , Quality of Life , Congenital Abnormalities , Buttocks , Cohort Studies , HIV , Retroviridae Infections , HIV-Associated Lipodystrophy Syndrome , Anti-Retroviral Agents , Lipodystrophy , Medication Systems , Congenital Abnormalities/surgery , Buttocks/surgery , HIV/drug effects , Retroviridae Infections/drug therapy , HIV-Associated Lipodystrophy Syndrome/drug therapy , Anti-Retroviral Agents/analysis , Anti-Retroviral Agents/pharmacology , Lipodystrophy/drug therapy , Medication Systems/history
9.
ACM arq. catarin. med ; 44(1): 93-105, jan. - mar. 2015. Tab
Article in Portuguese | LILACS | ID: biblio-1869

ABSTRACT

Objetivos: Identificar fatores associados ao uso do polimetilmetacrilato em pacientes HIV positivos sob tratamento antirretroviral em Santa Catarina e definir o perfil dos pacientes que buscam o tratamento para lipoatrofia facial. Métodos: Estudo transversal com 219 pacientes elaborado a partir de registros no SINAN (Sistema de Informação de Agravos de Notificação) e concomitantemente no serviço realizador da intervenção para lipoatrofia facial no âmbito do Sistema Único de Saúde no Estado de Santa Catarina, no período de 2008 a 2011, em que foram avaliados possíveis fatores de risco em variáveis sóciodemográficas e clínicas relacionadas à doença e à intervenção. Resultados: Os pacientes tinham em média 48 anos variando de 30 a 74 anos, sendo predominantemente do sexo masculino (70,8%). Foi encontrada associação significativa entre hipertensão arterial sistêmica (p=0,0006), sexo masculino (p=0,0010), realização de transfusão sanguínea (p=0,013), pacientes não etilistas (p=0,014) e portadores de HIV há mais de 5 anos (p=0,049) e a maior aplicação de polimetilmetacrilato. Em média, o grupo homossexual necessitou de quase 0,6 intervenções a mais do que o grupo heterossexual para uso de metacrilato, assim como maior volume (6,16mL). Conclusão: Pacientes do sexo masculino, homossexuais, hipertensos, que realizaram transfusão sanguínea, não etilistas e que possuem diagnóstico da doença há mais de 5 anos fizeram aplicação de maior volume de polimetilmetacrilato.


Objectives: Identify factors associated with use of polymethylmetacrylate HIV-infected patients in with treatment on antiretroviral in Santa Catarina and define the profile of patients seeking treatment for lipoatrophy. Methods: Cross-sectional study with 219 patients compiled from records in SINAN (Information System for Notifiable Diseases) and concurrently director of the service intervention for facial lipoatrophy in the SUS in the state of Santa Catarina, from 2008 to 2011, where they were assessed possible risk factors in clinical and sociodemographic variables related to illness and intervention. Results: Patients had an mean of 48 years ranging from 30 to 74 years, predominantly male (70.8%). There was use of higher volume of polymethyl methacrylate in the face of patients with hypertension (p = 0.0006), male gender (p = 0.0010), performance of blood transfusion (p = 0.013), non-alcoholic patients (p = 0.014) and HIV for over 5 years (p = 0.049). On mean, the homosexual group interventions needed almost 0.6 more than the heterosexual group for use methacrylate as well as higher volume (6.16 mL). Conclusion: Homossexual men, hypertensive, patients who underwent blood transfusion, nondrinkers as well as who have a diagnosis of the disease for more than 5 years showed increased risk for higher volume of polymethyl methacrylate in the face male patients.

10.
Int J STD AIDS ; 26(4): 279-84, 2015 Mar.
Article in English | MEDLINE | ID: mdl-24855130

ABSTRACT

Progression of lipodystrophy syndrome is a big challenge in HIV treatment. Nowadays, fat loss at the lower part of buttocks has become another problem as patients have started to complain that it is painful to be seated for a long time and/or on hard surfaces. We developed a method for buttock lipoatrophy treatment with PMMA-microspheres, as silicone prostheses and autologous fat transplant were not completely efficient. The treatment consisted of net-crossed injections, in the subcutaneous layer, of a 30% PMMA-microspheres solution on the atrophic areas of the buttock. One hundred and fifty-four patients were included. The amount of PMMA-microspheres used to treat buttock lipoatrophy depended on the degree of atrophy and size of the area to be treated. Patients were satisfied with this treatment and reported to be more comfortable to be seated for longer period of time. We demonstrated that soft tissue augmentation with PMMA-microspheres is safe and efficient for the treatment of buttock lipoatrophy associated with HIV lipodystrophy.


Subject(s)
Biocompatible Materials/administration & dosage , HIV-Associated Lipodystrophy Syndrome/therapy , Microspheres , Polymethyl Methacrylate/administration & dosage , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/adverse effects , Buttocks , Female , Follow-Up Studies , HIV Infections/drug therapy , Humans , Injections, Subcutaneous , Male , Middle Aged , Patient Satisfaction , Treatment Outcome
11.
Front Immunol ; 5: 507, 2014.
Article in English | MEDLINE | ID: mdl-25431572

ABSTRACT

OBJECTIVES: To investigate changing nutritional demographics of treated HIV-1-infected patients and explore causes of obesity, particularly in women of African origin. METHODS: We prospectively reviewed nutritional demographics of clinic attenders at an urban European HIV clinic during four one-month periods at three-yearly intervals (2001, 2004, 2007, and 2010) and in two consecutive whole-year reviews (2010-2011 and 2011-2012). Risk-factors for obesity were assessed by multiple linear regression. A sub-study of 50 HIV-positive African female patients investigated body-size/shape perception using numerical, verbal, and pictorial cues. RESULTS: We found a dramatic rise in the prevalence of obesity (BMI > 30 kg/m(2)), from 8.5 (2001) to 28% (2011-2012) for all clinic attenders, of whom 86% were on antiretroviral treatment. Women of African origin were most affected, 49% being obese, with a further 32% overweight (BMI 25-30 kg/m(2)) in 2012. Clinical factors strongly associated with obesity included female gender, black African ethnicity, non-smoking, age, and CD4 count (all P < 0.001); greater duration of cART did not predict obesity. Individual weight-time trends mostly showed slow long-term progressive weight gain. Investigating body-weight perception, we found that weight and adiposity were underestimated by obese subjects, who showed a greater disparity between perceived and actual adiposity (P < 0.001). Obese subjects targeted more obese target "ideal" body shapes (P < 0.01), but were less satisfied with their body shape overall (P = 0.02). CONCLUSION: Seropositive African women on antiretroviral treatment are at heightened risk of obesity. Although multifactorial, body-weight perception represents a potential target for intervention.

12.
Rev. cienc. med. Pinar Rio ; 18(2): 320-328, abr. 2014.
Article in Spanish | LILACS | ID: lil-740030

ABSTRACT

Introducción: la morbilidad y la mortalidad relacionadas con el VIH se han reducido ostensiblemente después del inicio de la era de la terapia antirretroviral de alta eficacia. La prevalencia de lipodistrofia en pacientes con la terapia antirretroviral es muy variable, los cambios pueden ser clínicamente sutiles al inicio, con signos de lipohipertrofia central y lipoatrofia periférica en los primeros estadios. Cuando la lipoatrofia afecta la cara y/o la grasa se acumula en la región cervicodorsal (joroba de búfalo), se considera lipodistrofia en estadios avanzados. Caso clínico: en la actual investigación se hace la presentación de un caso clínico, paciente femenina, piel negra de 43 años de edad que se diagnostica seropositiva al VIH en el mes de julio de 1999. Después de varios años de tratamiento, se comenzaron a observar cambios de la composición corporal de esta paciente con signos evidentes de lipodistrofia. Conclusiones: el síndrome de lipodistrofia se presenta como efecto adverso de la terapia antirretroviral en pacientes con sida provocando alteraciones morfológicas y metabólicas que afectan la adherencia al tratamiento. Las repercusiones estéticas provocan alteraciones psicológicas que afectan directamente a estos sujetos en las áreas afectiva, social y laboral. Se hace necesaria la realización de más estudios que permitan obtener mayores evidencias sobre este síndrome. De vital importancia resulta la adecuada evaluación de los pacientes seropositivos al VIH que consumen terapia antirretroviral por los profesionales de la salud, para lograr la identificación temprana del síndrome de lipodistrofia y aplicar métodos oportunos de tratamiento.


Introduction: HIV morbidity and mortality has substantially decreased with the use of HAART. The prevalence of lipodystrophy in HAART patients is greatly variable; clinically, the changes may be subtle at the beginning, with signs of central lipohypertrophy and peripheral lipoatrophy in early stages. When lipoatrophy affects the face and/or fat accumulates to the cervicodorsal region (buffalo hump), this is considered advanced lipodystrophy. Clinical case: female patient of black race, 43 years of age, diagnosed HIV-positive in July 1999. After several years of treatment, changes started to be noticed in her body constitution, with clear signs of lipodystrophy. Conclusions: the syndrome of lipodystrophy constitutes an adverse effect of HAART in AIDS patients, causing morphological and metabolic alterations that affects adherence to the treatment. Aesthetic repercussions provoke psychological alterations that affect these individuals directly in the affective, social and working areas. More research is needed for more evidence about this syndrome. The proper evaluation by health care professionals of HIV patients consuming HAART is vitally important, in order to timely diagnose the syndrome of lipodystrophy and apply fitting methods of treatments.

13.
Rev. Soc. Bras. Med. Trop ; 47(1): 30-37, Jan-Feb/2014. tab
Article in English | LILACS | ID: lil-703160

ABSTRACT

Introduction: The published literature shows an increased occurrence of adverse events, such as human immunodeficiency virus (HIV)-associated lipodystrophy syndrome, that are associated with the continuous use of antiretroviral therapy. This study was performed to estimate the prevalence and factors associated with lipodystrophy in acquired immune deficiency syndrome (AIDS) patients. Methods: We conducted a cross-sectional study between October 2012 and February 2013. The sample consisted of patients with AIDS who attended the Outpatient Treatment Center for Infectious Diseases at Nereu Ramos Hospital, Florianópolis, State of Santa Catarina, Brazil. We collected information on demographics, lifestyle, HIV infection, and clinical aspects of the disease. Self-reported signs of lipodystrophy and body measurements were used for lipodystrophy diagnosis. Results: We studied 74 patients (mean age 44.3±9.2 years; 60.8% men). Among the patients, 45.9% were smokers, 31.1% consumed alcoholic beverages, and 55.4% were sedentary. The prevalence of lipodystrophy was 32.4%, and sedentary subjects had a higher prevalence of lipodystrophy compared with physically active individuals. Conclusions: The prevalence of lipodystrophy was 32.4%. Physical activity was considered an independent protective factor against the onset of HIV-associated lipodystrophy. .


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Anti-HIV Agents/adverse effects , HIV-Associated Lipodystrophy Syndrome/epidemiology , Antiretroviral Therapy, Highly Active/adverse effects , Cross-Sectional Studies , HIV-Associated Lipodystrophy Syndrome/chemically induced , Life Style , Prevalence , Risk Factors , Socioeconomic Factors
14.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-443162

ABSTRACT

Objective To investigate the prevalence and risk factors of highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome (LD) in patients with acquired immunodeficiency syndrome (AIDS) treated with HAART in China.Methods A total of 137 AIDS patients treated with HAART for more than 2 years were analyzed.Sixteen clinical parameters (including gender,age,baseline body mass index,baseline human immunodeficiency virus [HIV] viral load,stage of disease,routes of HIV transmission,baseline CD4+ T lymphocyte count,white blood cell count,fasting plasma glucose level,serum triglycerides level,serum cholesterol level and other laboratory results,and HAART regimens) that might be associated with HAART-LD occurrence were evaluated using Cox proportional hazards models.Results HAART regimens were significantly correlated with HAART-LD (P=0.031),while the remaining 15 factors were not associated with the risk of HAART-LD (all P>0.05).Patients who received stavudine d4T)-containing regimen was 2.684 times more likely to develop HAART-LD than patients who received zidovudine (AZT)-containing regimen (95 % CI:1.302-5.531,P=0.007) ; HAART-LD prevalence rates were gradually increased with treatment duration in both groups.First HAART-LD was seen at 24 weeks in both d4T group and AZT group,and the prevalence rates were 2.7%,1.6% at 24 weeks,27.0%,7.9% at 48 weeks and 37.8%,15.9% at 96 weeks respectively.The prevalence of HAART-LD in d4T group was much higher than that in AZT group and the difference was statistically significant (x2 =8.285,P=0.004).Conclusions HAART regimen is an independent predictor of HAART-LD.HAART-LD tend to occur more frequently in patients treated with d4T or AZT,especially d4T.Our study recommends to avoid the use of d4T-contained HAART regimen.

15.
An. bras. dermatol ; 88(4): 570-577, ago. 2013. tab, graf
Article in English | LILACS | ID: lil-686517

ABSTRACT

BACKGROUND: HIV/AIDS-Associated Lipodystrophy Syndrome includes changes in body fat distribution, with or without metabolic changes. The loss of fat from the face, called facial lipoatrophy, is one of the most stigmatizing signs of the syndrome. OBJECTIVES: To evaluate the effect of FL treatment using polymethylmethacrylate (PMMA) implants on disease progression, assessed by viral load and CD4 cell count. METHODS: This was a prospective study of 44 patients treated from July 2009 to December 2010. Male and female patients, aged over 18 years, with clinically detectable FL and who had never been treated were included in the study. PMMA implantation was done to fill atrophic areas. Laboratory tests were conducted to measure viral load and CD4 count before and after treatment. RESULTS: Of the 44 patients, 72.72% were male and 27.27% female, mean age of 44.38 years. Before treatment, 82% of patients had undetectable viral load, which increased to 88.6% after treatment, but without statistical significance (p = 0.67). CD4 count before treatment ranged from 209 to 1293, averaging 493.97. After treatment, the average increased to 548.61. The increase in CD4 count after treatment was statistically significant with p = 0.02. CONCLUSION: The treatment of FL with PMMA implants showed a statistically significant increase in CD4 count after treatment, revealing the impact of FL treatment on disease progression. Viral load before ...


FUNDAMENTOS: A Síndrome Lipodistrófica Associada ao HIV/AIDS compreende alterações na distribuição da gordura corporal, acompanhada ou não de alterações metabólicas. A perda da gordura facial, chamada lipoatrofia facial, é dos sinais mais estigmatizantes da síndrome. OBJETIVOS: Avaliar o impacto do tratamento dalipoatrofia facial com implante de polimetilmetacrilato sobre a progressão da doença, avaliada pela contagem da carga viral e a contagem de células CD4. MÉTODOS: Estudo prospectivlipoatrofia facial clinicamente detectável e sem tratamento prévio. Foi realizado implante de polimetilmetacrilato para preenchimento das áreas atróficas. Foram realizadas contagem da carga viral e células CD4 antes e após o tratamento. RESULTADOS: Dos 44 pacientes, 72,72% eram do sexo masculino e 27,27% do feminino, e idade média de 44,38 anos. Antes do tratamento, 82% dos pacientes apresentavam carga viral indetectável, que aumentou para 88,6% após o tratamento, mas sem significância estatística (p=0,67). A contagem de CD4 antes do implante variou de 209 a 1293, com média de 493,97. Após o tratamento, essa média aumentou para 548,61. O aumento do CD4 após o tratamento foi estatisticamente significativo, com p=0,02. CONCLUSÃO: O tratamento dalipoatrofia facial com implante de polimetilmetacrilato ...


Subject(s)
Adult , Female , Humans , Male , Middle Aged , HIV-Associated Lipodystrophy Syndrome/therapy , Polymethyl Methacrylate/therapeutic use , Viral Load , Biocompatible Materials/therapeutic use , Disease Progression , Face , HIV-Associated Lipodystrophy Syndrome/immunology , HIV-Associated Lipodystrophy Syndrome/virology , Prospective Studies , Prostheses and Implants , Reference Values , Statistics, Nonparametric , Treatment Outcome
16.
Rev. salud pública ; 15(3): 446-454, mayo-jun. 2013. ilus, tab
Article in Spanish | LILACS | ID: biblio-962007

ABSTRACT

Objetivos Dado que la estavudina se ha asociado a toxicidad acumulativa e irreversible, se pretendió reducir la aparición de resultados negativos asociados al uso de estavudina mediante la notificación del riesgo a diferentes responsables de la atención sanitaria de pacientes con VIH/SIDA en Colombia. Métodos A partir de la base de datos de dispensación de medicamentos de Audifarma S.A a unos 4,5 millones de personas, se identificaron todos los usuarios de estavudina, se notificó el riesgo a los prestadores del servicio de salud y se recomendó la sustitución por zidovudina o tenofovir. Resultados En 2010 se identificaron 1 410 pacientes en tratamiento antirretroviral, de los cuales 109 (7,5 %) recibían estavudina, distribuidos en 20 ciudades del país y atendidos por 19 instituciones diferentes. Tras la intervención se consiguió en 28 meses reducir su empleo en 94,6 %. El medicamento más empleado en la sustitución fue zidovudina. Discusión Se consiguió exitosamente reemplazar estavudina siguiendo las recomendaciones de la Organización Mundial de la Salud, con lo cual se puede evitar la aparición de lipodistrofia y neuropatía periférica asociada a su empleo.(AU)


Objectives Reducing the occurrence of negative stavudine use-associated outcomes by reporting such risk to doctors responsible for the care of HIV/AIDS patients in Colombia as stavudine has been associated with cumulative and irreversible toxicity. Methods All stavudine users were identified from Audifarma S.A. (drug suppliers) databases (covering about 4.5million people). The risk was then reported to health service providers and the substitution of stavudine for zidovudine or tenofovir was recommended. Results It was found that 1,410 patients registered in the afore mentioned databases were receiving antiretroviral therapy during 2010, of whom 109 (7.5 %) were receiving stavudine; these patients were living in 20 cities and being attended by 19 institutions. Stavudine use became reduced by 94.6 % during the 28 months following the intervention. Zidovudine was the most commonly used replacement drug. Discussion Stavudine was successfully replaced following World Health Organization recommendations aimed at preventing the occurrence of lipodystrophy and the peripheral neuropathy associated with its use.(AU)


Subject(s)
Humans , Acquired Immunodeficiency Syndrome/drug therapy , HIV/drug effects , Stavudine/toxicity , HIV-Associated Lipodystrophy Syndrome , Zidovudine/administration & dosage , Colombia , Drug Substitution , Pharmacovigilance , Tenofovir/administration & dosage
17.
Rev. latinoam. enferm ; 20(5): 847-853, Sept.-Oct. 2012. tab
Article in English | LILACS, BDENF - Nursing | ID: lil-656185

ABSTRACT

OBJECTIVE: to identify the different types of morphological alterations from lipodystrophy syndrome (LS) in outpatients and relate them to the therapeutic regimen used. METHOD: a cross-sectional study which recruited 60 patients with HIV and LS and 79 without LS, who consented to interview and data collection from their medical notes. RESULTS: the region most affected by lipoatrophy was the face; by lipohypertrophy, the abdomen, and by the mixed form, the alterations to the abdomen, face, and upper and lower limbs. CONCLUSION: among the therapeutic regimens, that comprised of zidovudine, lamivudine and efavirenz seemed to protect against LS. Nursing can act in the early identification of the changes, as well as providing guidance and support for patients affected by the changes in their body image.


OBJETIVO: identificar os diferentes tipos de alterações morfológicas da síndrome da lipodistrofia (SL) em pacientes dos atendimentos ambulatoriais e relacioná-las ao esquema terapêutico utilizado. MÉTODO: estudo transversal, para o qual foram recrutados 60 pacientes com HIV e SL e 79 sem a SL, que consentiram entrevista e coleta de dados em prontuário. RESULTADOS: a região mais acometida pela lipoatrofia foi a face; pela lipo-hipertrofia o abdome e pela forma mista as alterações em abdome, face, membros superiores e inferiores. CONCLUSÃO: dentre os esquemas terapêuticos, o composto pela zidovudina, lamivudina e efavirenz pareceu proteger contra a SL. A enfermagem pode atuar na identificação precoce das alterações, além de fornecer orientações e apoio aos pacientes acometidos pelas mudanças na imagem corporal.


OBJETIVO: identificar los diferentes tipos de alteraciones morfológicas del Síndrome de la lipodistrofia (SL) en pacientes de los servicios de ambulatorio y relacionarlas al esquema terapéutico utilizado. MÉTODO: estudio transversal en lo que fueron reclutados 60 pacientes con VIH y la SL y 79 sin la SL, que consintieron entrevista y recogida de datos en prontuario. RESULTADOS: la región más acometida por la lipoatrofia fue la cara; por la lipohipertrofia el Abdomen y por la forma mixta las alteraciones en Abdomen, cara, miembros superiores e inferiores. CONCLUSIÓN: entre los esquemas terapéuticos, el compuesto por la zidovudina, lamivudina y efavirenz pareció proteger contra la SL. La enfermería puede actuar en la identificación precoz de las alteraciones, además de suministrar orientaciones y apoyo a los pacientes acometidos por los cambios en la imagen corporal.


Subject(s)
Adult , Female , Humans , Male , Anti-HIV Agents/adverse effects , HIV Infections/drug therapy , Lipodystrophy/chemically induced , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , Cross-Sectional Studies
18.
Rev. bras. cir. plást ; 27(3): 387-391, jul.-set. 2012. ilus
Article in English, Portuguese | LILACS | ID: lil-668137

ABSTRACT

INTRODUÇÃO: O início do tratamento da síndrome da imunodeficiência adquirida (AIDS) com a terapia antirretroviral de alta atividade (HAART), na década de 1990, aumentou, consideravelmente, a longevidade e a qualidade de vida dos portadores da doença. A redução da morbidade e da mortalidade associadas a doenças infecciosas e neoplásicas oportunistas, porém, tem sido acompanhada pelo aumento da prevalência de outras doenças, entre elas a lipodistrofia associada ao vírus da imunodeficiência humana (HIV). A lipodistrofia decorre da toxicidade de drogas utilizadas na terapia antirretroviral, sendo atribuída aos inibidores de protease e aos inibidores da transcriptase reversa análogos do nucleosídeo. Este trabalho aborda a lipoatrofia facial, que confere um aspecto de envelhecimento precoce e traz de volta o velho estigma da "facies da AIDS", podendo impactar negativamente na qualidade de vida dos portadores de HIV. MÉTODO: Neste estudo foram incluídos 41 pacientes apresentando lipoatrofia facial, que foram submetidos a preenchimento com polimetilmetacrilato (PMMA) no Hospital Universitário da Universidade Federal de Juiz de Fora (HU-UFJF) e na clínica Plastic Center, Clínica de Cirurgia Plástica em Juiz de Fora, no período entre janeiro de 2010 e fevereiro de 2012. RESULTADOS: O número de procedimentos realizados em cada paciente variou de 1 a 4, sendo respeitado um intervalo mínimo de 90 dias entre eles. A quantidade de PMMA utilizado variou de acordo com o grau e a região a serem corrigidos, ficando entre 3 ml e 18 ml por procedimento. Em todos os pacientes, o resultado obtido foi favorável esteticamente. CONCLUSÕES: Os resultados obtidos pela bioplastia com PMMA foram considerados satisfatórios pelos pacientes. O material utilizado possui alta adaptabilidade às áreas receptoras, necessitando apenas da modelagem e da quantidade adequada para que apresente bom padrão estético.


BACKGROUND: When the treatment of acquired immunodeficiency syndrome (AIDS) with highly active antiretroviral therapy (HAART) began in the 1990s, it considerably increased the life expectancy and quality of life of AIDS patients. However, the decrease in morbidity and mortality associated with opportunistic infectious and neoplastic diseases was accompanied by an increase in the prevalence of other diseases, including HIV-associated lipodystrophy. Lipodystrophy is due to the toxicity of drugs used in antiretroviral therapy, including protease inhibitors and nucleoside analog reverse transcriptase inhibitors. This article discusses the treatment of facial lipodystrophy, which confers an appearance of premature aging and brings back the old stigma of the "AIDS face," which negatively impacts the quality of life of HIV carriers. METHODS: Forty-one patients with facial lipoatrophy received filling with polymethylmethacrylate (PMMA) at the Hospital Universitário da Universidade Federal de Juiz de Fora (HU-UFJF) and at the Plastic Center Clinic, Plastic Surgery Clinic in Juiz de Fora between January 2010 and February 2012. RESULTS: Patients received 1 to 4 procedures with a minimum interval of 90 days between procedures. The amount of PMMA used ranged from 3 to 18 mL per procedure according to the degree and region to be corrected. The results were aesthetically favorable in all patients. CONCLUSIONS: The results obtained through bioplasty with PMMA are considered satisfactory by patients. The material used is highly adaptable to the receiving areas, requiring only modeling and an adequate amount in order to obtain good aesthetic results.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , History, 21st Century , Surgery, Plastic , Aging , Acquired Immunodeficiency Syndrome , HIV , Polymethyl Methacrylate , Antiretroviral Therapy, Highly Active , HIV-Associated Lipodystrophy Syndrome , Drug-Related Side Effects and Adverse Reactions , Lipid Metabolism , Face , Lipodystrophy , Surgery, Plastic/methods , Aging/drug effects , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/therapy , Polymethyl Methacrylate/therapeutic use , Antiretroviral Therapy, Highly Active/methods , HIV-Associated Lipodystrophy Syndrome/surgery , HIV-Associated Lipodystrophy Syndrome/therapy , Drug-Related Side Effects and Adverse Reactions/therapy , Lipid Metabolism/physiology , Face/surgery , Lipodystrophy/surgery , Lipodystrophy/drug therapy
19.
Rev. saúde pública ; 46(4): 737-746, Aug. 2012. tab
Article in English, Portuguese | LILACS | ID: lil-646476

ABSTRACT

OBJETIVO: Analisar o efeito do tratamento nutricional sobre as alterações metabólicas provocadas pelo uso da terapia antirretroviral em adultos vivendo com HIV/aids. MÉTODOS: Revisão sistemática de literatura no PubMed, Lilacs e Cochrane, entre 1996 e 2010, do tipo ensaio clínico, controlado, randomizado, crossover, adultos, vivendo com HIV/aids em uso de terapia antirretroviral e sem doenças oportunistas. A intervenção de interesse foi suplementação nutricional via oral e/ou mudança de estilo de vida por tratamento dietoterápico específico: dislipidemia, resistência insulínica, lipodistrofia e hipertensão arterial sistêmica. A escala de Jadad foi utilizada para classificação qualitativa dos artigos. RESULTADOS: Foram localizados 385 artigos e sete foram incluídos. As intervenções utilizadas nesses estudos foram: dieta, dieta mais exercício físico, dieta mais suplemento e somente suplementos. Dislipidemia foi desfecho avaliado em todos os estudos. Os estudos que avaliaram suplementação com ômega 3 encontraram redução significativa dos triglicérides. Dieta específica mais suplementação de ômega 3 mostrou aumento de HDL-colesterol. Suplementação com nicotinato de cromo não teve efeito sobre a dislipidemia. Modificação de estilo de vida, incluindo dieta e atividade física, reduziu significativamente a circunferência da cintura, lipodistrofia e pressão arterial sistólica. CONCLUSÕES: A redução de triglicérides pela suplementação com ômega 3 foi a intervenção nutricional com maiores evidências científicas. A prescrição de dieta específica parece ser a intervenção mais adequada para aumentar HDL-colesterol. Não é possível fazer inferências sobre o tratamento nutricional do colesterol total, LDL-colesterol e resistência insulínica. Modificações no estilo de vida podem promover melhora da lipodistrofia e pressão arterial.


OBJECTIVE: To analyze the effect of nutritional treatment on metabolic changes caused by the use of antiretroviral therapy in adults with HIV/AIDS. METHODS: A systematic review of literature was conducted in the PubMed, Lilacs and Cochrane databases, between 1996 and 2010, including crossover and randomized controlled clinical trials performed in adults with HIV/AIDS using antiretroviral therapy and without opportunistic diseases. The intervention of interest was oral nutritional supplementation and/or a change in lifestyle due to specific dietary treatment: dyslipidemia, insulin resistance, lipodystrophy and systemic arterial hypertension. The Jadad scale was used for a qualitative classification of articles. RESULTS: A total of 385 articles were found, of which seven were included. The interventions used in these studies were as follows: diet, diet and physical exercises, diet and supplementation, and only supplementation. Dyslipidemia was the outcome assessed in all studies. Studies that assessed omega-3 supplementation found a significant reduction in triglycerides. The specific diet with omega-3 supplementation showed an increase in HDL-cholesterol. Chrome nicotinate supplementation did not have an effect on dyslipidemia. Changing one's lifestyle, including diet and physical activity, significantly reduced waist circumference, lipodystrophy and systolic blood pressure. CONCLUSIONS: Reduction in tryglicerides with omega-3 supplementation was the nutritional intervention with the strongest scientific evidence. Prescribing a specific diet appeared to be the most adequate intervention to increase HDL-cholesterol. Inferences could not be made about the nutritional treatment of total cholesterol, LDL-cholesterol and insulin resistance. Changes in lifestyle can promote an improvement in lipodystrophy and blood pressure.


Subject(s)
Humans , Male , Female , Adult , Dietary Supplements , Dyslipidemias/diet therapy , HIV-Associated Lipodystrophy Syndrome/diet therapy , Antiretroviral Therapy, Highly Active/adverse effects , Cholesterol/blood , Clinical Trials as Topic , Exercise , /therapeutic use , Insulin Resistance , Life Style , Triglycerides/blood
20.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 58(1): 70-75, jan.-fev. 2012. tab
Article in English | LILACS | ID: lil-617111

ABSTRACT

OBJECTIVE: Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects. METHODS: A total of 819 patients followed at a large outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied on agreement between patient's self-report and physician's observation of altered body-fat deposits. The presence of three or more of the following characteristics identified MS: increased waist circumference, hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic regression analyses to study variables independently associated with MS. RESULTS: The prevalence of MS was 20.6 percent and that of lipodystrophy was 38.5 percent. 61 (36.1 percent) out of 169 patients with MS had also lipodystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer exposure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome. CONCLUSION: Both traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with metabolic syndrome in the present study population.


OBJETIVO: A prevalência de complicações crônicas da infecção HIV está aumentando, e o reconhecimento precoce e o tratamento dos componentes da síndrome metabólica (SM) são essenciais para a prevenção de complicações cardiovasculares e metabólicas. Considerando isso, realizamos um estudo transversal sobre prevalência e fatores de risco para SM em indivíduos HIV+. MÉTODOS: Um total de 819 pacientes acompanhados em um ambulatório de HIV foi avaliado por um entrevistador que registrou em questionário dados demográficos, epidemiológicos, clínicos, laboratoriais e variáveis sociais. O diagnóstico de lipodistrofia baseou-se na concordância entre autorrelato do paciente e observação do médico das alterações de gordura corporal. A SM foi identificada pela presença de três ou mais das seguintes características: circunferência abdominal aumentada, hipertrigliceridemia, colesterol HDL baixo, hipertensão e hiperglicemia. Análises de regressão logística foram utilizadas para identificar variáveis associadas à SM. RESULTADOS: A prevalência de SM foi 20,6 por cento e de lipodistrofia foi 38,5 por cento. Entre os 169 pacientes com SM, 61 (36,1 por cento) apresentavam lipodistrofia. Os pacientes com síndrome metabólica tinham, significativamente, maior probabilidade de ser mais velhos (OR = 1,08), ter maior contagem de CD4 (OR = 1,001), ter maior índice de massa corporal (OR = 1,27) e ter maior tempo de exposição à terapia antirretroviral (OR = 1,01). CONCLUSÃO: Tanto fatores de risco tradicionais para doença cardiovascular quanto fatores associados à infecção HIV, como aumento da contagem de CD4 e maior exposição à terapia antirretroviral, parecem estar associados à SM na população estudada.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , HIV Infections/complications , HIV-Associated Lipodystrophy Syndrome/epidemiology , Lipodystrophy/epidemiology , Metabolic Syndrome/epidemiology , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Cross-Sectional Studies , HIV Infections/drug therapy , HIV-Associated Lipodystrophy Syndrome/chemically induced , Lipodystrophy/chemically induced , Metabolic Syndrome/complications , Prevalence , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...